News
Lilly's obesity pill lags Novo's Wegovy injection in key trial
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's injectable obesity treatment Wegovy.
Lilly's Weight Loss Pill Falls Short of Novo's Wegovy in Key Study
Eli Lilly's GLP-1 pill, orforglipron, led to 12.4% weight loss in a 72-week study, falling short of Novo Nordisk's Wegovy. Despite the results, Lilly plans to seek global approval, highlighting the pill's potential for convenience and its heart health benefits.
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...
Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, ...
Eli Lilly's experimental GLP-1 pill, orforglipron, helped patients lose 12.4% of their body weight in a late-stage study, ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback